Immunocore appoints CMO
This article was originally published in Scrip
Immunocore, a biotechnology company developing drugs to treat cancer, viral infections and autoimmune disease, has named Christina Coughlin chief medical officer. Dr Coughlin will be responsible for providing medical and regulatory leadership to the preclinical and clinical programs for the company. Most recently, Dr Coughlin was leading two early development program at Novartis in checkpoint inhibition and PI3'kinase inhibition. Prior to this she was international project team leader at Morphotek, a monoclonal antibody company acquired by Eisai in 2007.
You may also be interested in...
The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.
Johan Van Hoof, global head of vaccines at Janssen, talks to In Vivo about the company’s platform, how it is approaching COVID-19 research and the impact of today’s global pandemic on the future of vaccine R&D.
Emerging Company Profile: Irish start-up Shorla Pharma recently secured $8.3m to move its pipeline candidates into the clinic. While it is not the largest series A financing for an emerging biotech, the company expects to get its first “re-innovated” product approved in the US next year.